Episodes
Saturday Jan 06, 2024
Do Statins “REPRIEVE” People Living with HIV from CV Events?
Saturday Jan 06, 2024
Saturday Jan 06, 2024
As people living with HIV age, the risk of cardiovascular disease becomes the greatest threat to their health and quality of life. Not only does inflammation from HIV infection contribute to atherosclerotic cardiovascular disease (ASCVD), but dyslipidemia from the antivirals commonly used to treat HIV further enhances that risk. But does statin therapy reduce ASCVD risk in patients living with HIV? That's the question that the REPRIEVE study attempted to answer.
Guest Authors: Laura Lerner, PharmD and Joseph Nardolillo, PharmD, BCACP
Music by Guest Talk
Thursday May 24, 2018
Cutting Down HIV Treatment to a 2-Drug Regimen
Thursday May 24, 2018
Thursday May 24, 2018
While multi-drug combination therapies for HIV has resulted in longer lifespans, simplified medication regimens are needed to reduce pill-burden in an aging population with HIV. Two-drug regimens are potentially attractive because they may minimize drug exposure; reduce risks for adverse effects, drug-drug interactions, and long-term toxicities; and potentially increase patient adherence. The SWORD-1 and SWORD-2 trials evaluated the efficacy and safety of a two-drug regimen to maintain viral suppression in HIV infected patients.
Guest Authors Tinh An (April) Nguyen, PharmD and Jihae Lim, PharmD
Music by Good Talk